The clinical-stage assets are shown as below. There are also ten plus pre-clinical assets in our pipeline. 
    • Product Indication Progress
    • Discovery Pre-clinical Phase1 Phase2 Phase3  
    • AN2025 (Buparlisib) HNSCC  

      AN2025 is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. It has shown promising efficacy in combination with paclitaxel in HNSCC and received a Fast-Track designation and an approval for initiating the phase III clinical study from FDA.

    • AN0025 (EP4 Antagonist ) solid tumor  

      AN0025(EP4 Antagonist)is an investigational, potentially first in class oral EP4 antagonist that in preclinical models prevents the binding of prostaglandin E2 to its EP4 receptor to change the immunosuppressive character of the tumor microenvironment. Based on preliminary results, it is well tolerated in patients with solid tumors. A Phase 1b study of AN0025 in combination with the standard of care for locally advanced rectal cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by MRI has been finished. With nearly 40% of patients not requiring surgery or achieving a complete pathological response in the post-surgical specimen in this study, AN0025 in combination with the standard pre-operative treatment warrants further development.

    • AN1004 (Pelareorep) breast cancer  

      Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients. Pelareorep has received Fast Track designation and Special Protocol Assessment Agreement for phase III clinical trial from FDA for the treatment of metastatic breast cancer. And we also received approvsl from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China.

    • Product Indication
    • Ganirelix Acetate Injection Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovulation. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilisation.
    • Carbetocin Injection Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin — it causes contraction of the uterus.
    • Desmopressin Acetate Tablets Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.

    TTechnical reserve: Bivalirudin for Injection, Thymalfasin for Injection, Atosiban Acetate Injection, Terlipressin for Injection, linaclotide Capsule, Degarelix for Injection, Liraglutide Injection, Ziconotide Injection, Insulin Detemir Injection, Teriparatide Injection etc.

    We provide technology optimization, preparation technology of peptide and protein drug for a number of well-known domestic pharmaceutical enterprises.

    Technical services are mainly related to generic technology of peptide and protein, not involving the new drugs research and development technology secrets.